Metabolic Modulation as Treatment in Acute Heart Failure

• Status: Terminated
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to evaluate whether metabolic modulation improves hemodynamics and outcome in acute heart failure

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Aarhus
• Treatments: Acipimox

Criteria

Inclusion Criteria:

• Acute heart failure

• NYHA class III - IV.

• ejection fraction <35

Exclusion Criteria:

• Age <18 år or >85 år,

• allergy

• renal failure

• recently developed brady- or tachy-arrythmias

• Serious infection

• Heart failure due to restrictive or hypertrophic cardiomyopathy or stenotic valvular heart disease

• Recent Myocardial infarction (<6 Weeks)

• Pulmonary Wedge pressure >30 mm Hg

• diabetes mellitus treated with insulin

• peptic ulcer

• pregnancy